![]() ![]() | Schettini, F., Venturini, S., Giuliano, M., Lambertini, M., Pinato, D. J., Onesti, C. E., De Placido, P., Harbeck, N., Lüftner, D., Denys, H., Van Dam, P., Arpino, G., Zaman, K., Mustacchi, G., Gligorov, J., Awada, A., Campone, M., Wildiers, H., Gennari, A., ... Generali, D. (December 2022). Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer. Cancer Treatment Reviews, 111, 102468. doi:10.1016/j.ctrv.2022.102468 ![]() |
![]() ![]() | ONESTI, C. E., Schroeder, H., Rorive, A., Sautois, B., Lecocq, M., Goffin, M., Gonne, E., Collinge, A., Nicolaers, L., Wéra, O., Catot, A., Loly, C., Paulus, A., Sibille, A., Lousberg, L., Troisfontaine, F., Collignon, J., Gennigens, C., Frères, P., ... Jerusalem, G. (2021). Oncological patients' reactions to COVID-19 pandemic: A single institution prospective study. Cancer Reports, 1571. doi:10.1002/cnr2.1571 ![]() |
![]() ![]() | Poncin, A., Onesti, C. E., JOSSE, C., Boulet, D., Thiry, J., Bours, V., & Jerusalem, G. (August 2021). Immunity and Breast Cancer: Focus on Eosinophils. Biomedicines, 9 (9), 1087. doi:10.3390/biomedicines9091087 ![]() |
![]() ![]() | Onesti, C. E., & Jerusalem, G. (2021). CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Review of Anticancer Therapy, 21 (3), 283-298. doi:10.1080/14737140.2021.1852934 ![]() |
![]() ![]() | ONESTI, C. E., Tagliamento, M., Curigliano, G., Harbeck, N., Bartsch, R., Wildiers, H., Tjan-Heijnen, V., Martin, M., Rottey, S., Generali, D., Campone, M., Cristofanilli, M., Pusztai, L., Peeters, M., Berchem, G., Cortes, J., Ruhstaller, T., Ciruelos, E., Rugo, H. S., & Jerusalem, G. (2021). Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. JCO global oncology, 7, 162-172. doi:10.1200/GO.20.00589 ![]() |
![]() ![]() | Schettini, F., Giuliano, M., Lambertini, M., Bartsch, R., Pinato, D. J., ONESTI, C. E., Harbeck, N., Rottey, S., Van Dam, P. A., Zaman, K., Mustacchi, G., Gligorov, J., Awada, A., Campone, M., Wildiers, H., Gennari, A., Tjan-Heijnen, V. C. G., Cortes, J., Locci, M., ... Generali, D. (2021). Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. Cancers, 13 (17), 4421. doi:10.3390/cancers13174421 ![]() |
![]() ![]() | Onesti, C. E., JOSSE, C., Boulet, D., Bours, V., & JERUSALEM, G. (2020). High plasmatic levels of IL-4 and IL- 13 are associated with recurrence and worse survival in breast cancer. Tumori Journal. ![]() |
![]() ![]() | ONESTI, C. E., JOSSE, C., Beaumecker, B., Boulet, D., Thiry, J., BOURS, V., & JERUSALEM, G. (2020). The relative eosinophil count in breast cancer as an emerging prognostic biomarker. European Journal of Cancer. doi:10.1016/S0959-8049(20)30766-8 ![]() |
![]() ![]() | Carneiro, A., Amaral, T., Brandao, M., Scheffler, M., Boj, K., Ferrara, R., Jalving, M., Lo Russo, G., Marquez-Rodas, I., Matikas, A., Mezquita, L., Morgan, G., ONESTI, C. E., Pilotto, S., Saloustros, E., & Trapani, D. (2020). Disparities in access to oncology clinical trials in Europe in the period 2009-2019. Annals of Oncology. ![]() |
![]() ![]() | JERUSALEM, G., ONESTI, C. E., Generali, D., Harbeck, N., Wildiers, H., Curigliano, G., Campone, M., Tjan-Heijnen, V., Martin, M., Cristofanilli, M., Pusztai, L., Bartsch, R., Peeters, M., Berchem, G., Tagliamento, M., Cortès, J., Ruhsthaller, T., Ciruelos, E., Rottey, S., & Rugo, H. (2020). Expected medium and long term impact of the COVID-19 outbreak in oncology. Annals of Oncology. ![]() |
![]() ![]() | ONESTI, C. E., Rugo, H. S., Generali, D., Peeters, M., Zaman, K., Wildiers, H., Harbeck, N., Martin, M., Cristofanilli, M., Cortes, J., Tjan-Heijnen, V., Hurvitz, S. A., Berchem, G., Tagliamento, M., Campone, M., Bartsch, R., De Placido, S., Puglisi, F., Rottey, S., ... JERUSALEM, G. (August 2020). Oncological care organisation during COVID-19 outbreak. ESMO Open, 5. doi:10.1136/esmoopen-2020-000853 ![]() |
![]() ![]() | ONESTI, C. E., JOSSE, C., Boulet, D., Thiry, J., Beaumecker, B., BOURS, V., & JERUSALEM, G. (2020). Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse. Oncoimmunology. doi:10.1080/2162402X.2020.1761176 ![]() |
![]() ![]() | ONESTI, C. E., SCHROEDER, H., RORIVE, A., SAUTOIS, B., LECOCQ, M., Goffin, M., GONNE, E., COLLINGE, A., NICOLAERS, L., WERA, O., Catot, A., LOLY, C., PAULUS, A., SIBILLE, A., LOUSBERG, L., Troisfontaine, F., COLLIGNON, J., GENNIGENS, C., FRERES, P., & JERUSALEM, G. (2020). How do oncological patients perceive the Covid-19 (SARS-CoV-2) pandemic ? Experience from CHU Liege in Belgium [Poster presentation]. ESMO Virtual Congress 2020, Madrid, Spain. |
![]() ![]() | LECOCQ, M., ONESTI, C. E., SCHROEDER, H., RORIVE, A., Goffin, M., GONNE, E., SAUTOIS, B., Catot, A., WERA, O., NICOLAERS, L., COLLINGE, A., Collignon, J., FRERES, P., POLUS, M., DUYSINX, B., VAILLANT, F., GENNIGENS, C., MARCHAL, N., PONCIN, A., & JERUSALEM, G. (2020). Risk of SARS-CoV-2 infection and outcome after infection : Experience from the day-care unit at CHU Liege in Belgium [Poster presentation]. ESMO Virtual Congress 2020, Madrid, Spain. |
![]() ![]() | ONESTI, C. E., BOEMER, F., JOSSE, C., LEDUC, S., Poulet, C., BOURS, V., & JERUSALEM, G. (2019). Tryptophan catabolism differentiates breast cancer patients from healthy controls but does not predict outcome. Annals of Oncology. ![]() |
![]() ![]() | ONESTI, C. E., FRERES, P., & JERUSALEM, G. (2019). Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients’ treatment. Journal of Thoracic Disease. doi:10.21037/jtd.2018.12.47 ![]() |
![]() ![]() | Onesti, C. E., Iacono, D., Angelini, S., Mazzotta, M., Giusti, R., Lauro, S., & Marchetti, P. (2019). Four lines of anaplastic lymphoma kinase inhibitors and brain radiotherapy in a long-surviving non-small-cell lung cancer anaplastic lymphoma kinase-positive patient with leptomeningeal carcinomatosis. Anti-Cancer Drugs, 30 (2), 201-204. doi:10.1097/CAD.0000000000000699 ![]() |
![]() ![]() | ONESTI, C. E., BOEMER, F., JOSSE, C., LEDUC, S., BOURS, V., & JERUSALEM, G. (2019). Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy. Journal of Translational Medicine, 17, 239. doi:10.1186/s12967-019-1984-2 ![]() |
![]() ![]() | ONESTI, C. E., JOSSE, C., Poncin, A., FRERES, P., Poulet, C., BOURS, V., & JERUSALEM, G. (2018). Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment. Oncotarget. doi:10.18632/oncotarget.26120 ![]() |
![]() ![]() | ONESTI, C. E., JOSSE, C., PONCIN, A., FRERES, P., Poulet, C., BOURS, V., & JERUSALEM, G. (13 September 2018). Predictive and prognostic role of peripheral blood eosinophil count in triple negative and hormone receptor negative/HER2 positive breast cancers patients undergoing neoadjuvant treatment [Paper presentation]. GIGA-Cancer Day 2018 / EDT-Cancerology Vascular landscape and (pre)metastatic niche in cancer biology. |
![]() ![]() | Roberto, M., Botticelli, A., Strigari, L., Ghidini, M., ONESTI, C. E., Ratti, M., Benzoni, I., Pizzo, C., Falcone, R., Lomiento, D., Donida, B. M., Totaro, L., Mazzuca, F., & Marchetti, P. (19 June 2018). Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival. Medical Oncology, 35 (7), 111. doi:10.1007/s12032-018-1166-8 ![]() |
![]() ![]() | Botticelli, A., Cerbelli, B., Lionetto, L., Zizzari, I., Pisano, A., Roberto, M., ONESTI, C. E., Di Pietro, F., Napoletano, C., Pizzuti, L., Vici, P., D'Amati, G., Mazzuca, F., Simmaco, M., Nuti, P., & Marchetti, P. (2018). The key role of kynurenine in antiPD-1 failure. Cancer Research. ![]() |
![]() ![]() | Milano, A., Mazzetta, F., Valente, S., Ranieri, D., Leone, L., Botticelli, A., ONESTI, C. E., Lauro, S., Raffa, S., Torrisi, M. R., & Marchetti, P. (2018). Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice. Analytical Cellular Pathology. doi:10.1155/2018/3506874 ![]() |
![]() ![]() | Occhipinti, M., Falcone, R., ONESTI, C. E., & Marchetti, P. (2018). Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report. Drug Safety - Case Reports, 5 (1), 12. doi:10.1007/s40800-018-0078-z ![]() |
![]() ![]() | Mazzuca, F., ONESTI, C. E., Roberto, M., Di Girolamo, M., Botticelli, A., Begini, P., Strigari, L., Marchetti, P., & Mazzuca, F. (2018). Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines. Oncotarget. doi:10.18632/oncotarget.25394 ![]() |
![]() ![]() | Botticelli, A., Putignani, L., Zizzari, I., Del Chierico, F., Reddel, S., Di Pietro, F., Quagliarello, ONESTI, C. E., Giusti, R., Mazzuca, F., Nuti, M., & Marchetti, P. (2018). Changes of microbiome profile during nivolumab treatment in NSCLC patients. Journal of Clinical Oncology, 36 (suppl), 15020. ![]() |
![]() ![]() | Occhipinti, M., Falcone, R., ONESTI, C. E., Botticelli, A., Mazzuca, F., Marchetti, P., & Lauro, S. (November 2017). Crizotinib plus radiotherapy in brain oligoprogressive NSCLC ROS1 rearranged and PD-L1 strong. Journal of Thoracic Disease, 9 (11), 985-E989. doi:10.21037/jtd.2017.09.74 ![]() |
![]() ![]() | Botticelli, A., ONESTI, C. E., Zizzari, I., Cerbelli, B., Sciattella, P., Occhipinti, M., Roberto, M., Di Pietro, F., Bonifacino, A., Ghidini, M., Vici, P., Pizzuti, L., Napoletano, C., Strigari, L., D'Amati, G., Mazzuca, F., Nuti, M., & Marchetti, P. (November 2017). The sexist behaviour of immune checkpoint inhibitors in cancer therapy? Oncotarget, 8 (59), 99336-99346. doi:10.18632/oncotarget.22242 ![]() |
![]() ![]() | Occhipinti, M., Botticelli, A., ONESTI, C. E., Ghidini, M., Righini, R., Pizzo, C., Milano, A., Tomasello, G., Di Pietro, F. R., Toppo, L., Ratti, M., Passalacqua, R., Marchetti, P., & Mazzuca, F. (October 2017). Treatment and outcome for small bowel adenocarcinoma (SBA): a real life experience of two Italian centres. Annals of Oncology, 28 (Suppl 6). doi:10.1093/annonc/mdx425.022 ![]() |
![]() ![]() | Botticelli, A., ONESTI, C. E., Strigari, L., Occhipinti, M., Di Pietro, F., Cerbelli, B., Petremolo, A., Anselmi, E., Macrini, S., Roberto, M., Falcone, R., Lionetto, L., Borro, M., Milano, A., Gentile, G., Simmaco, M., Marchetti, P., & Mazzuca, F. (June 2017). A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient. Anti-Cancer Drugs, 28 (5), 551-556. doi:10.1097/CAD.0000000000000492 ![]() |
![]() ![]() | Angelini, S., Botticelli, A., ONESTI, C. E., Giusti, R., Sini, V., Durante, V., Strigari, L., Gentile, G., Cerbelli, B., Pellegrini, P., Sgroi, V., Occhipinti, M., Di Pietro, F., Rossi, A., Simmaco, M., Mazzuca, F., & Marchetti, P. (May 2017). Pharmacogenomics Approach to Toxicity in Breast Cancer Patients Treated with Taxanes. Anticancer Research, 37 (5), 2633-2639. doi:10.21873/anticanres.11610 ![]() |
![]() ![]() | ONESTI, C. E., Botticelli, A., La Torre, M., Borro, M., Gentile, G., Romiti, A., Lionetto, L., Petremolo, A., Occhipinti, M., Roberto, M., Falcone, R., Simmaco, M., Marchetti, P., & Mazzuca, F. (March 2017). 5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX. Anti-Cancer Drugs, 28 (3), 322-326. doi:10.1097/CAD.0000000000000453 ![]() |
![]() ![]() | Roberto, M., Romiti, A., Botticelli, A., Mazzuca, F., Lionetto, L., Gentile, G., Paris, I., Falcone, R., Bassanelli, M., Di Pietro, F., ONESTI, C. E., Anselmi, E., Macrini, S., Simmaco, M., & Marchetti, P. (February 2017). Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine. European Journal of Clinical Pharmacology, 73 (2), 157-164. doi:10.1007/s00228-016-2160-8 ![]() |
![]() ![]() | Borro, M., Botticelli, A., Mazzuca, F., ONESTI, C. E., Gentile, G., Romiti, A., Cerbelli, B., Mazzotti, E., Marchetti, L., Lionetto, L., Simmaco, M., & marchetti, P. (February 2017). Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer. Oncotarget, 8 (8), 14050-14057. doi:10.18632/oncotarget.12571 ![]() |
![]() ![]() | Toppo, L., Liguigli, W., Senti, C., Tomasello, G., Ghidini, M., Ratti, M., Botticelli, A., ONESTI, C. E., Di Pietro, F., Pizzo, C., Panni, S., Curti, A., & Passalacqua, R. (2017). Presence of bone metastases(BM) at diagnosis is associated with poor prognosis and coagulation disorders (CD) in patients (pts) with advanced gastric cancer (AGC). Journal of Clinical Oncology, 35. ![]() |
![]() ![]() | ONESTI, C. E., Botticelli, A., Occhipinti, M., Di Pietro, F., Zizzari, I., Napoletano, C., Nuti, M., Lauro, S., Mazzuca, F., & Marchetti, P. (2017). Early onset of endocrine alterations during PD-1 blockade in advanced NSCLC patients. Annals of Oncology, 28S (Suppl 2). ![]() |
![]() ![]() | Ghidini, M., Botticelli, A., Donida, B. M., Strigari, L., ONESTI, C. E., Ratti, M., Pizzo, C., Aldighieri, F., Toppo, L., Ranieri, V., Occhipinti, M., Senti, C., Tanzi, G., Mazzuca, F., Marchetti, P., Martinotti, M., Passalaqua, R., Tomasello, G., & Rovatti, M. (2017). Prognostic factors associated with survival and recurrence in resectable gastroesophageal adenocarcinoma: retrospective analysis of 497 patients operated at two Italian centers. Journal of Clinical Oncology, 35. ![]() |
![]() ![]() | Nuti, M., Zizzari, I., Napoletano, C., Botticelli, A., Calabro, F., Gelibter, A., Rughetti, A., Ugolini, A., Ruscito, I., Mazzuca, F., Rahimi, H., ONESTI, C. E., Cortesi, E., & Marchetti, P. (2017). Immunomodulatory effects of tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC) patients. Journal of Clinical Oncology, 35. ![]() |
![]() ![]() | Botticelli, A., Cerbelli, B., Pernazza, A., ONESTI, C. E., Sciattella, P., Costarelli, L., Monti, M., Cmpagna, D., Mazzuca, F., Fortunato, L., Marchetti, P., & D'Amati, G. (2017). PD-L1 expression in TNBC: A predictive biomarker of response to neoadjuvant chemotherapy? Annals of Oncology, 28 (Suppl 5), 30. ![]() |
![]() ![]() | D'Antonio, C., Lombardini, A., ONESTI, C. E., Falcone, R., Romiti, A., Lombardi, M., Lauro, S., & Marchetti, P. (December 2016). A rare case of palatin tonsillar metastasis from small cell lung cancer. Translational Lung Cancer Research, 5 (6), 709-711. doi:10.21037/tlcr.2016.11.07 ![]() |
![]() ![]() | Falcone, R., Roberto, M., D'Antonio, C., Romiti, A., Milano, A., ONESTI, C. E., Marchetti, P., & Fais, S. (2016). High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: A case series and the state of art. Digestive and Liver Disease. doi:10.1016/j.dld.2016.08.126 ![]() |
![]() ![]() | ONESTI, C. E., Iacono, D., Angelini, S., Lauro, S., Mazzotta, M., Occhipinti, M. A., Giusti, R., & Marchetti, P. (December 2016). Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: a single-center experience and review of the literature. Translational Lung Cancer Research, 5 (6), 712-719. doi:10.21037/tlcr.2016.09.01 ![]() |
![]() ![]() | Romiti, A., Roberto, M., D'Antonio, C., ONESTI, C. E., Barucca, V., Milano, A., Gentile, G., Lionetto, L., Medda, E., Mazzuca, F., Botticelli, A., Falcone, R., Simmaco, M., & Marchetti, P. (November 2016). The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer. Anti-Cancer Drugs, 27 (10), 1044-9. doi:10.1097/CAD.0000000000000429 ![]() |
![]() ![]() | Botticelli, A., Borro, M., ONESTI, C. E., Strigari, L., Gentile, G., Cerbelli, B., Romiti, A., Occhipinti, M., Sebastiani, C., Lionetto, L., Marchetti, L., Simmaco, M., Marchetti, P., & Mazzuca, F. (September 2016). Degradation rate of 5-fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker? PLoS ONE, 11 (9), 0163105. doi:10.1371/journal.pone.0163105 ![]() |
![]() ![]() | Roberto, M., Romiti, A., ONESTI, C. E., Zullo, A., Falcone, R., & Marchetti, P. (July 2016). Evolving treatments for advanced gastric cancer: appraisal of the survival trend. Expert Review of Anticancer Therapy, 16 (7), 717-29. doi:10.1080/14737140.2016.1184979 ![]() |
![]() ![]() | Roberto, M., Romiti, A., ONESTI, C. E., D'Antonio, C., Milano, A., Falcone, R., Barucca, V., Palombi, L., Righini, R., & Marchetti, P. (February 2016). A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer. Anti-Cancer Drugs, 27 (2), 106-11. doi:10.1097/CAD.0000000000000308 ![]() |
![]() ![]() | ONESTI, C. E., Botticelli, A., Mazzuca, F., Milano, A., Romiti, A., Roberto, M., Falcone, R., Occhipinti, M., Di Pietro, F. R., Lionetto, L., Simmaco, M., & Marchetti, P. (2016). 5-fluorouracil degradation rate (5-FU-DR) as a new toxicity predictive biomarker for adjuvant FOLFOX in colorectal cancer (CRC) patients. Annals of Oncology, 27 (Suppl 6). doi:10.1093/annonc/mdw370.134 ![]() |
![]() ![]() | Roberto, M., Romiti, A., Pilozzi, E., Balducci, G., Ferri, M., Uccini, S., Falcone, R., Campisi, G., Mercantini, P., Mazzuca, F., Di Pietro, F. R., ONESTI, C. E., Botticelli, A., & Marchetti, P. (2016). Is the benefit of adjuvant chemotherapy limited to high risk stage II colorectal cancer ? Annals of Oncology. doi:10.1093/annonc/mdw335.24 ![]() |
![]() ![]() | ONESTI, C. E., Botticelli, A., Mazzuca, F., Angelini, S., Petremolo, A., Falcone, R., Roberto, M., Occhipinti, M., Romiti, A., Lionetto, L., Simmaco, M., & Marchetti, P. (2016). 5-fluorouracil degradation rate (5-FU-DR) could predict toxicity in breast cancer patients treated with capecitabine. Annals of Oncology, 27 (Suppl 4), 68. doi:10.1093/annonc/mdw337.29 ![]() |
![]() ![]() | Roberto, M., Romiti, A., Botticelli, A., Di Pietro, F. R., Lionetto, L., Gentile, G., Mazzuca, F., Falcone, R., Occhipinti, M., Macrini, S., Anselmi, E., Petremolo, A., ONESTI, C. E., Simmaco, M., & Marchetti, P. (2016). 5-fluorouracil degradation rate as a predictive toxicity biomarker in early stage gastrointestinal cancer. Annals of Oncology, 27 (Suppl 6). doi:10.1093/annonc/mdw363.48 ![]() |
![]() ![]() | ONESTI, C. E., Vicier, C., & André, F. (November 2015). What to expect from high throughput genomics in metastatic breast cancers? Breast, 24 (Suppl 2), 19-22. doi:10.1016/j.breast.2015.07.006 ![]() |
![]() ![]() | ONESTI, C. E., Romiti, A., Roberto, M., Falcone, R., & Marchetti, P. (September 2015). Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure. Expert Review of Anticancer Therapy, 15 (10). doi:10.1586/14737140.2015.1081816 ![]() |
![]() ![]() | Di Girolamo, M., Paris, I., Carbonetti, F., ONESTI, C. E., Socciarelli, F., & Marchetti, P. (July 2015). Widespread renal polycystosis induced by crizotinib. Tumori Journal, 101 (4), 128-31. doi:10.5301/tj.5000338 ![]() |
![]() ![]() | Romiti, A., ONESTI, C. E., Roberto, M., Barucca, V., Tomao, S., D'Antonio, C., Durante, V., Milano, A., Falcone, R., Di Rocco, R., Righini, R., & Marchetti, P. (March 2015). Continous, low-dose capecitabine for patients with recurrent colorectal cancer. Medical Oncology, 32 (3), 54. doi:10.1007/s12032-015-0496-z ![]() |
![]() ![]() | Roberto, M., Romiti, A., Lionetto, L., D'Antonio, C., ONESTI, C. E., Botticelli, A., Milano, A., Falcone, R., Occhipinti, M., Mazzuca, F., Simmaco, M., & Marchetti, P. (2015). 5-Fluorouracil degradation rate in patients with recurrent gastrointestinal cancer treated with metronomic capecitabine. Annals of Oncology, 27 (Suppl 2). doi:10.1093/annonc/mdw199.37 ![]() |
![]() ![]() | Lauro, S., Angelini, S., ONESTI, C. E., Occhipinti, M., Iacono, D., Righini, R., Giusti, R., Simmaco, M., & Marchetti, P. (2015). Genetic polymorphism can help physician choosing the best cancer chemotherapy. Annals of Oncology, 26 (Suppl 6), 84-vi85. doi:10.1093/annonc/mdv343.39 ![]() |
![]() ![]() | Deluche, E., ONESTI, C. E., & Andre, F. (2015). Precision medicine for metastatic breast cancer. American Society of Clinical Oncology Educational Book, 2-7. doi:10.14694/EdBook_AM.2015.35.e2 ![]() |
![]() ![]() | Lauro, S., Righini, R., ONESTI, C. E., Pucci, E., Bramini, A., & Marchetti, P. (December 2014). Gastric metastases from testicular cancer: case report and review of literature. Journal of Gastrointestinal Cancer, 45 (Suppl 1), 22-4. doi:10.1007/s12029-013-9524-4 ![]() |
Roberto, M., D'Antonio, C., Romiti, A., Milano, A., Falcone, R., Durante, V., Mazzuca, F., ONESTI, C. E., Barucca, V., Righini, R., & Marchetti, P. (24 October 2014). Metronomic capecitabine in metastatic colorectal cancer: a phase II trial [Poster presentation]. XVI Congresso Nazionale AIOM. |
Milano, A., Mazzetta, F., Raffa, S., Valente, S., Righini, R., ONESTI, C. E., Paris, I., Lauro, S., Torrisi, M. R., & Marchetti, P. (24 October 2014). Epithelial and mesenchimal molecular markers in circulating tumor cells (CTCs) from non-small cells lung cancer (NSCLC) patients [Poster presentation]. XVI Congresso Nazionale AIOM. |
![]() ![]() | D'Antonio, C., Milano, A., Righini, R., ONESTI, C. E., Bassanelli, M., Falcone, R., Paris, I., Lauro, S., & Marchetti, P. (October 2014). Pharmacogenomics in lung cancer chemotherapy: a review of what the oncologist should know. Anticancer Research, 34 (10), 5241-50. ![]() |
![]() ![]() | Lauro, S., ONESTI, C. E., Righini, R., & Marchetti, P. (April 2014). The use of bevacizumab in non-small cell lung cancer: an update. Anticancer Research, 34 (4), 1537-45. ![]() |
![]() ![]() | Lauro, S., ONESTI, C. E., Righini, R., Carbonetti, F., Cremona, A., & Marchetti, P. (2014). A Synchronous Pancreatic Metastasis from Renal Clear Cell Carcinoma, with Unusual CT Characteristics, Completely Regressed after Therapy with Sunitinib. Case Reports in Medicine, 473431. doi:10.1155/2014/473431 ![]() |
![]() ![]() | Carbonetti, F., ONESTI, C. E., Rampioni, G., Cremona, A., Lauro, S., Marchetti, P., & Mattei, M. (2014). Breast Metastasis of Thymic Carcinoma. British Journal of Medicine and Medical Research, 4 (24), 4178-85. ![]() |
![]() ![]() | Paris, I., Prelaj, A., ONESTI, C. E., Baldoni, A., Giovagnoli, M. R., Bassanelli, M., Lauro, S., & Marchetti, P. (January 2014). Esophageal stenosis: a differential diagnosis between esophageal cancer and metastasis from other neoplasia. Anticancer Research, 34 (1), 363-66. ![]() |
![]() ![]() | Lauro, S., ONESTI, C. E., Righini, R., D'Antonio, C., Simmaco, M., Zazzara, M. B., Bramini, A., & Marchetti, P. (2014). Relation between polymorphisms and chemotherapy in lung cancer. European Journal of Cancer, 50, 53-54. ![]() |
D'Antonio, C., Romiti, A., Lombardini, A., Durante, V., Milano, A., Mazzuca, F., Sarcina, I., Falcone, R., ONESTI, C. E., Iacono, D., Righini, R., Palombi, L., & Marchetti, P. (11 October 2013). MTHFR C677T gene polymorphisms and susceptibility to cardiovascular adverse events in metastatic colorectal cancer treated with chemotherapy plus bevacizumab [Poster presentation]. XV Congresso Nazionale AIOM. |
![]() ![]() | Vecchione, A., Belletti, B., Lovat, F., Volinia, S., Chiappetta, G., Giglio, S., Sonego, M., Cirombella, R., ONESTI, C. E., Pellegrini, P., Califano, D., Pignata, S., Losito, S., Canzonieri, V., Sorio, R., Alder, H., Wernicke, D., Stoppacciaro, A., Baldassarre, G., & Croce, C. M. (June 2013). A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 110 (24), 9845-50. doi:10.1073/pnas.1305472110 ![]() |